<DOC>
	<DOC>NCT02309827</DOC>
	<brief_summary>This study is a first in human study of PF-06651600. PF-06651600 is being developed for treatment of inflammatory bowel disease. This study will test single and multiple doses of PF-06651600. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06651600 in healthy volunteers.</brief_summary>
	<brief_title>Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male/female subjects between 18 and 55 years old, inclusive. Females must be of nonchild bearing potential. BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Evidence of personally signed and dated informed consent document. Willing and able to comply with scheduled visits, treatment plan, lab tests and other study procedures. Subjects must avoid high intensity UV light exposure (eg, active sunbathing, tanning beds/booths or sunlamps) from the first dose of study drug and for the duration of the study. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, GI, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Use of tobacco/nicotine containing products in excess of 5 cigarettes/day. History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males. Screening blood pressure &gt;140/90 mm Hg. Screening laboratory abnormalities as defined by the protocol. Unwilling or unable to comply with the Lifestyle Guidelines as defined by the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Inflammatory bowel disease</keyword>
</DOC>